BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu LH, Mei J, Kan A, Ling YH, Li SH, Wei W, Chen MS, Zhang YF, Guo RP. Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. Cancer Med. 2020;9:2997-3005. [PMID: 32108433 DOI: 10.1002/cam4.2951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang D, Zhuang B, Wang Y, Xie X, Xie X. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol 2020;20:402. [PMID: 33246417 DOI: 10.1186/s12876-020-01544-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ma L, Deng K, Zhang C, Li H, Luo Y, Yang Y, Li C, Li X, Geng Z, Xie C. Nomograms for Predicting Hepatocellular Carcinoma Recurrence and Overall Postoperative Patient Survival. Front Oncol 2022;12:843589. [PMID: 35296018 DOI: 10.3389/fonc.2022.843589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu LH, Mei J, Kan A, Ling YH, Li SH, Wei W, Chen MS, Zhang YF, Guo RP. Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. Cancer Med. 2020;9:2997-3005. [PMID: 32108433 DOI: 10.1002/cam4.2951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
4 Chen ZY, Guo ZX, Lu LH, Mei J, Lin WP, Li SH, Wei W, Guo RP. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma. Cancer Med 2021;10:5466-74. [PMID: 34212527 DOI: 10.1002/cam4.4102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhou Y, Qiu J, Liu S, Wang P, Ma D, Zhang G, Cao Y, Hu L, Wang Z, Wu J, Jiang C. CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway. Cancer Med 2022. [PMID: 35861040 DOI: 10.1002/cam4.4919] [Reference Citation Analysis]
6 Liu J, Zhao J, Gu HAO, Zhu Z. Repeat hepatic resection VS radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis. Minim Invasive Ther Allied Technol 2020;:1-10. [PMID: 33143517 DOI: 10.1080/13645706.2020.1839775] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wei M, Zhang Y, Chen M, Chen Y, Lau W, Peng Z. Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy. Front Oncol 2022;12:868429. [DOI: 10.3389/fonc.2022.868429] [Reference Citation Analysis]
8 Chen Z, Wang J, Lin Y. Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis. World J Surg Oncol 2022;20:182. [PMID: 35668464 DOI: 10.1186/s12957-022-02649-4] [Reference Citation Analysis]
9 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Aquina CT, Eskander MF, Pawlik TM. Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Front Oncol 2022;12:832405. [DOI: 10.3389/fonc.2022.832405] [Reference Citation Analysis]
11 Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, Ju Z, Rao J, Lu L. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med 2020;9:8159-72. [PMID: 32977361 DOI: 10.1002/cam4.3411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Yang Y, Yu H, Tan X, You Y, Liu F, Zhao T, Qi J, Li J, Feng Y, Zhu Q. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2021;38:875-86. [PMID: 34078221 DOI: 10.1080/02656736.2021.1933218] [Reference Citation Analysis]
13 Shi T, Xu C, Feng Y, Wei Y, Lv H, Zhu Q. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2022. [PMID: 35694799 DOI: 10.1097/MEG.0000000000002393] [Reference Citation Analysis]
14 Kim HS, Yi NJ, Kim JM, Joh JW, Lee KW, Suh KS. Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection. Ann Surg Treat Res 2021;101:85-92. [PMID: 34386457 DOI: 10.4174/astr.2021.101.2.85] [Reference Citation Analysis]
15 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
16 Sun X, Li L, Lyu N, Mu L, Lai J, Zhao M. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging 2020;20:42. [PMID: 32611383 DOI: 10.1186/s40644-020-00319-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]